Chimeric nanoparticles for targeting mitochondria in cancer cells

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Mitochondrial dysfunction is linked to numerous diseases, notably cancer.
• Targeting mitochondrial DNA (mt-DNA) is an emerging cancer therapy strategy.
• Cancer cells can evade therapies targeting single mitochondrial components.

Purpose of the Study:

• To engineer novel mitochondria-targeting nanoparticles for multi-target cancer therapy.
• To simultaneously impair mitochondrial DNA, mitochondrial topoisomerase I, and mitochondrial ribosomes.
• To evaluate the efficacy of these nanoparticles against various cancer cell lines.

Main Methods:

• Developed cholesterol-based chimeric nanoparticles (mt-CNPs) loaded with cisplatin, camptothecin, and tigecycline.
• Characterized mt-CNPs for charge, shape, and size (187 nm).
• Utilized confocal microscopy to track mt-CNP localization in A549 lung cancer cells and assessed mitochondrial damage and ROS generation.

Main Results:

• mt-CNPs demonstrated efficient mitochondrial localization within 6 hours.
• Observed significant mitochondrial morphology damage and increased reactive oxygen species (ROS) production.
• mt-CNPs exhibited superior cancer-cell killing capabilities compared to free drug combinations in A549, HeLa, and MCF7 cells.

Conclusions:

• Engineered mt-CNPs effectively target multiple mitochondrial components simultaneously.
• This multi-target strategy shows significant potential for overcoming cancer cell resistance.
• These nanoparticles offer a promising new avenue for developing advanced cancer therapies.